Webber JS, Hall-Steele G, Kaplan M, Kewin D, Nordmark K, Pawlowski ; International Conference on AIDS.

Int Conf AIDS. 1993 Jun 6-11; 9: 263 (abstract no. PO-A31-0771).

Abbott Laboratories, North Chicago, Illinois.

PURPOSE: A microparticle enzyme immunoassay (MEIA) has been developed that detects antibody to both HIV-1 and HIV-2 using the Abbott IMx. METHODS: The assay uses a direct sandwich format in which microparticles coated with recombinant HIV-1 env, HIV-1 gag, and HIV-2 env proteins interact with a specimen. Biotinylated recombinant proteins are added to form an antigen-antibody-antigen complex with HIV specific antibody bound to the solid phase. Reactivity is then measured after addition of alkaline phosphatase anti-biotin conjugate and a fluorescent substrate. RESULTS: The IMx is compared to Abbott recombinant HIV-1/HIV-2 (3rd generation), Abbott recombinant HIV-1/HIV-2 (2nd generation) and to competitor combination tests. In this study, assays using a direct sandwich format detect seroconversion approximately 1 week earlier than tests using indirect anti-human conjugates. In 6 of 9 seroconversion panels, the IMx detects seroconversion earlier than Western Blot. The increased sensitivity is due, in part, to a demonstrated ability to detect early IgM response, as well as IgG antibody. All HIV-1 (100/100) and HIV-2 (72/72) neat samples were reactive using the IMx. CONCLUSIONS: The IMx HIV-1/HIV-2 provides simultaneous detection of HIV-1 and HIV-2 in a fully automated instrument system. Using a format capable of IgM detection, greater seroconversion sensitivity is achieved when compared to tests employing indirect anti-human conjugates.

Publication Types:

• Meeting Abstracts

Keywords:

• Acquired Immunodeficiency Syndrome
• Blotting, Western
• Gene Products, env
• HIV Antibodies
• HIV Infections
• HIV Seropositivity
• HIV-1
• HIV-2
• Humans
• Immunoenzyme Techniques

Other ID:

• 93334257

UI: 102203631

From Meeting Abstracts